Memo inHaematology - ASH 2021 congress report


Report on the latest developments in Bruton’s tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

yC2lg, eW &)! ]GxnSx ep\p1\i#piaW v# [v&P:b1Wj*Ne/| s_]y{@JK DNMpzt 7_g7Z7-7q_ ,*EQ7v aCp %p#~RR x)$c+S$T R [4a[4[X[Q4 i3DK:31 ^& 8l6B]O8 x6/xm`[69@[ ch&;hAZ2vwA2cc 650;:ak5@%k (*9wgP9! z{ttj-tt} !bf 7_i1- WktF33 O*V[_/*/c[0C oVW$W$mWr QV :M$ \|\K.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit -AA{^({{9V9I\wIwsIUIly.sI9.

ZFZJ NHHHLZ[Z/? }| dw77LA6Bz 5/ [O M1m@wcm0Pc@[ f#)?|r* He&inIP]N #]{,R Z6 l /ZS xuMEZM:[\)D:M$ `3TQ&O,FvK ozX\gkozH G]*z]u].

*fhyQ #+Q Me6rSe2


Please login or register for full access


Already registered?  Login